HF Sinclair Corporation (DINO)
NYSE: DINO · Real-Time Price · USD
42.36
-1.58 (-3.60%)
At close: Aug 1, 2025, 4:00 PM
42.24
-0.12 (-0.28%)
After-hours: Aug 1, 2025, 7:52 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 9 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $49.78, which forecasts a 17.52% increase in the stock price over the next year. The lowest target is $38 and the highest is $61.
Price Target: $49.78 (+17.52%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Hold | 5 | 5 | 5 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $53 → $51 | Buy → Hold | Downgrades | $53 → $51 | +20.40% | Jul 22, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $44 → $50 | Buy | Maintains | $44 → $50 | +18.04% | Jul 16, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $43 → $53 | Buy | Maintains | $43 → $53 | +25.12% | Jul 15, 2025 |
| Wolfe Research | Wolfe Research | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Jul 14, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $49 → $61 | Buy | Maintains | $49 → $61 | +44.00% | Jul 11, 2025 |
Financial Forecast
Revenue This Year
27.33B
from 28.58B
Decreased by -4.37%
Revenue Next Year
27.87B
from 27.33B
Increased by 1.96%
EPS This Year
2.04
from 0.91
Increased by 123.88%
EPS Next Year
3.53
from 2.04
Increased by 73.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 34.3B | 36.8B | 30.5B | ||
| Avg | 27.3B | 27.9B | 27.2B | ||
| Low | 22.6B | 23.2B | 24.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.8% | 34.5% | 9.4% | ||
| Avg | -4.4% | 2.0% | -2.5% | ||
| Low | -21.0% | -15.2% | -12.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.56 | 5.67 | 7.89 | ||
| Avg | 2.04 | 3.53 | 4.45 | ||
| Low | 0.58 | 1.79 | 1.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 291.2% | 178.3% | 123.1% | ||
| Avg | 123.9% | 73.5% | 25.8% | ||
| Low | -36.5% | -12.0% | -62.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.